FRESCO-2: Fruquintinib in Patients with Refractory Metastatic CRC

Arvind N. Dasari, MD, MS, provides a comprehensive overview of the FRESCO-2 trial investigating fruquintinib in patients with refractory metastatic colorectal cancer.

Related Keywords

,Adverse Event Management ,Colorectal Cancer ,Optimizing Treatment Approaches ,Refractory Metastatic ,Crc ,Colorectal Cancer Treatment ,Mcrc Treatment ,Fresco 2 ,Fruquintinib ,Refractory Colorectal Cancer ,Refractory Crc ,Bevacizumab ,Immunotherapy ,Tas 102 ,Regorafenib ,Safety Profile ,Toxicity ,Sunlight Trial ,